TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
7.56
-0.49 (-6.09%)
At close: Jan 31, 2025, 4:00 PM
7.55
-0.01 (-0.13%)
After-hours: Jan 31, 2025, 7:59 PM EST
TransCode Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for RNAZ stock has a target of 20, which predicts an increase of 164.55% from the current stock price of 7.56.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 18, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for RNAZ is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $20 | Strong Buy | Maintains | $3 → $20 | +164.55% | Dec 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $99 | Strong Buy | Reiterates | $99 | +1,209.52% | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $99 | Strong Buy | Reiterates | $99 | +1,209.52% | Oct 24, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $99 | Strong Buy | Reiterates | $99 | +1,209.52% | Sep 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $99 | Strong Buy | Reiterates | $99 | +1,209.52% | Aug 15, 2024 |
Financial Forecast
Revenue This Year
306.00K
Revenue Next Year
n/a
from 306.00K
EPS This Year
-4.86
EPS Next Year
-4.46
from -4.86
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 315,000 | n/a | 525,000 | |||
| Avg | 306,000 | n/a | 510,000 | |||
| Low | 294,000 | n/a | 490,000 |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -5.00 | -4.59 | -1.03 | |||
| Avg | -4.86 | -4.46 | -1.00 | |||
| Low | -4.66 | -4.28 | -0.96 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.